Clinical trials: Cancer Stem Cells
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment
By doing this study, researchers hope to learn the following: If providing hyperbaric oxygen (HBO) therapy prior to an umbilical cord blood (UBC) transplant will help to improve the homing process The safety of HBO administration…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome (MDS), Hodgkins Lymphoma
- Trial name
- NCT02099266
- Testing
- Administration of hyperbaric oxygen
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Kansas Medical Center
Leukemia, Lymphoma
AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders
RATIONALE: Giving chemotherapy with or without total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00547196
- Testing
- filgrastim, Busulfan, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- City of Hope Medical Center
Hematopoietic Cell Transplantation Recipient, Refractory B-Cell Non-Hodgkin Lymphoma
Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
This phase I/II trial studies the side effects and best dose of gemcitabine hydrochloride, clofarabine, and busulfan before donor stem cell transplant and to see how well it works in treating patients with B-cell or T-cell…
- Conditions
- Hematopoietic Cell Transplantation Recipient, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT01701986
- Testing
- Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Graft Versus Host Disease, Hematopoietic/Lymphoid Cancer
Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases
This pilot clinical trial studies donor stem cell transplant followed by cyclophosphamide in treating patients with hematological diseases.
- Trial name
- NCT02248597
- Testing
- fludarabine phosphate, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Wake Forest University Health Sciences
Extramedullary Plasmacytoma, Isolated Plasmacytoma of Bone
Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
This phase II trial investigates whether patients greater than or equal to 65 years of age diagnosed with myeloma or another plasma cell malignancy will have better outcomes with transplant followed by maintenance therapy, as…
- Conditions
- Extramedullary Plasmacytoma, Isolated Plasmacytoma of Bone, Light Chain Deposition Disease, Primary Systemic Amyloidosis
- Trial name
- NCT01849783
- Testing
- dexamethasone, cisplatin, doxorubicin
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Margarida Magalhaes-Silverman
Leukemia
Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia
RATIONALE: Giving chemotherapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT00274846
- Testing
- aldesleukin, therapeutic allogeneic lymphocytes, cyclophosphamide
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Ganglioneuroblastoma, Localized Resectable Neuroblastoma
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
This pilot clinical trial studies induction therapy followed by iobenguane I 131 and chemotherapy in treating patients with newly diagnosed high-risk neuroblastoma undergoing stem cell transplant, radiation therapy, and…
- Conditions
- Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma
- Trial name
- NCT01175356
- Testing
- 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Busulfan
- Where
- 25 sites in United States
- Volunteers
- 99 people
- Sponsor
- Children's Oncology Group
Lymphoma, Disorder Related to Bone Marrow Transplantation
Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma
The goal of this clinical research study is to see if receiving a transplant of blood stem cells (cells that can produce blood) or bone marrow from either a related donor (brother, sister or other relative) or an unrelated…
- Trial name
- NCT00506129
- Testing
- Fludarabine, Melphalan, Allogeneic Transplant
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- M.D. Anderson Cancer Center
Hematological Malignancy
Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis
The purpose of this study is to determine if Bortezomib, known commercially as Velcade is safe and tolerated at different dose levels (amounts) with high dose Cyclophosphamide to be used as graft versus host disease prevention…
- Trial name
- NCT01860170
- Testing
- Cohort 1-Bortezomib (Velcade ®), Cohort 2-Bortezomib (Velcade ®), Cohort 3-Bortezomib (Velcade ®)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Corewell Health West
Multiple Myeloma
Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma
The purpose of this study is to determine if the addition of daratumumab to lenalidomide-bortezomib-dexamethasone (RVd) will increase the proportion of participants achieving stringent complete response (sCR), as defined by the…
- Trial name
- NCT02874742
- Testing
- Lenalidomide, Bortezomib, Dexamethasone
- Where
- 36 sites in United States
- Volunteers
- 224 people
- Sponsor
- Janssen Research & Development, LLC
Plasma Cell Myeloma
Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation
This pilot randomized Phase II trial (10 subjects per arm) will compare immune reconstitution following transplantation of an autologous mobilized graft product to reconstitution following transplantation of a mobilized graft…
- Trial name
- NCT02700841
- Testing
- Melphalan, Peripheral Blood Stem Cell Transplantation--CD34 HSCT, Peripheral Blood Stem Cell Transplantation--AHSCT
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Nebraska
Leukemia
Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia
RATIONALE: Giving chemotherapy before a donor stem cell transplant using stem cells that closely match the patient's stem cells, helps stop the growth of cancer cells.
- Trial name
- NCT00553202
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- 52 sites in United States, Canada
- Volunteers
- 158 people
- Sponsor
- Children's Oncology Group
Lymphoma
Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)
The goal of this clinical research study is to study the safety of ADCETRISTM (brentuximab vedotin) in patients with Hodgkin lymphoma or ALCL who have had an allogeneic or haploidentical stem cell transplant.
- Trial name
- NCT02169505
- Testing
- Brentuximab Vedotin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
The study is designed as a Phase III, multi-center trial of tandem autologous transplants versus the strategy of autologous followed by Human Leukocyte Antigen (HLA)-matched sibling non-myeloablative allogeneic transplant.
- Trial name
- NCT00075829
- Testing
- One Autologous Transplant, Non-Myeloablative Allogeneic Transplant, Second Autologous Transplant
- Where
- 36 sites in United States
- Volunteers
- 710 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT
This is a multi-center, phase I/II clinical trial for patients who have relapsed more than 60 day after allogeneic transplant for a hematologic malignancy. The study consists of two phases.
- Conditions
- Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndromes (MDS), Lymphoma
- Trial name
- NCT01885897
- Testing
- ALT-803
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Leukemia, Myeloid, Myelodysplastic Syndromes
Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease
The purpose of this study is to determine the maximum tolerated dose, dose limiting side effects, and the safety of increasing doses of lenalidomide in patients with AML and MDS who have a small amount of detectable disease after…
- Trial name
- UF-BMT-MRD-101 (NCT02370888)
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Florida
Stem Cell Transplantation, Leukemia
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin
The goal of this clinical research study is to learn about the safety of AMD3100 (plerixafor) and G-CSF (filgrastim) in combination with fludarabine, busulfan, and an allogeneic blood stem cell transplant.
- Trial name
- NCT00822770
- Testing
- Plerixafor, Filgrastim, Fludarabine
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- M.D. Anderson Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Adult Acute Lymphoblastic Leukemia in Remission
Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
This randomized phase II trial studies how well vaccine therapy works in reducing the frequency of cytomegalovirus severe infections (events) in patients with hematologic malignancies undergoing donor stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Hodgkin Lymphoma
- Trial name
- NCT02396134
- Testing
- CMVpp65-A*0201 peptide vaccine, Laboratory Biomarker Analysis
- Where
- 5 sites in United States
- Volunteers
- 61 people
- Sponsor
- City of Hope Medical Center
Myelodysplastic Syndrome, Acute Lymphocytic Leukemia
Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation
Background: One way to treat certain cancers of the blood and immune system is to give a patient stem cells from the bone marrow of a donor whose genes are very similar but not identical to the patients.
- Conditions
- Myelodysplastic Syndrome, Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia
- Trial name
- NCT01338987
- Testing
- First Allogeneic Bone Marrow Transplant (BMT), Leuprolide, 18F FLT
- Where
- 3 sites in United States
- Volunteers
- 76 people
- Sponsor
- National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia in Remission
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies
This pilot clinical trial studies the side effects of irradiated donor cells following stem cell transplant in controlling cancer in patients with hematologic malignancies.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia in Remission, Hematopoietic Cell Transplantation Recipient, JAK2 Gene Mutation
- Trial name
- NCT03272633
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Irradiated Allogeneic Cells
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Rutgers, The State University of New Jersey